• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

    1.560 +0.170 (+12.23%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about GeoVax Labs, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology
    License Strengthens GeoVax’s Immuno-Oncology Strategy and Expands Intellectual Property Foundation for Combination Therapies Across Solid Tumors 
    Via TheNewswire.com
    Topics Intellectual Property
    News headline image
    GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Intellectual Property
    News headline image
    GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over
    Company Highlights GEO-MVA Manufacturing Readiness and Clear Clinical Pathway to Support Global Supply Diversification 
    Via TheNewswire.com
    News headline image
    GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Regulatory Compliance
    GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
    Via TheNewswire.com
    GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    ATLANTA, GA - February 13, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX) (the “Company”), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and... 
    Via TheNewswire.com
    Topics Regulatory Compliance
    News headline image
    GeoVax Highlights 2026 as a Pivotal Year for Progress
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    GeoVax Highlights 2026 as a Pivotal Year for Progress
    Management Highlights 2026 as a Portfolio-Wide Inflection Year Driven by Regulatory De-Risking, Clinical Readouts, and Scalable Manufacturing 
    Via TheNewswire.com
    GeoVax Addresses Identification of New Mpox Variant
    Via TheNewswire.com
    Topics Supply Chain
    GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board
    Via TheNewswire.com
    News headline image
    GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
    Via TheNewswire.com
    GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
    Via TheNewswire.com
    News headline image
    GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    News headline image
    GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Regulatory Compliance
    GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
    Via TheNewswire.com
    Topics Regulatory Compliance
    News headline image
    GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
    Via TheNewswire.com
    News headline image
    GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    News headline image
    GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Supply Chain
    GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
    Via TheNewswire.com
    Topics Supply Chain
    News headline image
    GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Intellectual Property
    GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
    Via TheNewswire.com
    Topics Intellectual Property
    News headline image
    GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
    Via TheNewswire.com
    News headline image
    GeoVax Addresses Identification of New Mpox Variant
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Supply Chain
    News headline image
    GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    News headline image
    GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Intellectual Property
    GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
    Via TheNewswire.com
    Topics Intellectual Property
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.